步长制药 - Financials

步长制药 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	11.0B	13.2B	15.0B	15.8B	16.0B
Revenue Growth %	-16.9%	-11.4%	-5.2%	-1.5%	--
Total Revenue	11.0B	13.2B	15.0B	15.8B	16.0B
Cost Of Revenue	4.4B	4.2B	4.2B	4.1B	3.7B
+Gross Profit	6.6B	9.0B	10.7B	11.6B	12.3B
Gross Margin %	59.8%	68.2%	71.7%	73.8%	76.6%
Total Operating Cost	11.3B	12.9B	16.3B	14.3B	13.8B
Selling Expenses	4.3B	6.4B	7.5B	8.3B	8.4B
Admin Expenses	1.0B	996.0M	902.0M	937.0M	839.0M
Rd Expenses	345.0M	335.0M	284.0M	409.0M	533.0M
Finance Expenses	123.0M	91.7M	114.0M	141.0M	118.0M
+Operating Income	-247.0M	436.0M	-1.2B	1.6B	2.4B
Operating Margin %	-2.2%	3.3%	-8.4%	10.3%	14.8%
Non Operating Income	4.9M	7.8M	4.5M	2.5M	2.7M
Non Operating Expenses	123.0M	49.3M	14.4M	36.5M	7.4M
Investment Income	13.0M	21.3M	2.7M	17.6M	15.6M
Fair Value Change Income	-149,300	-2.4M	--	-60.0M	--
Asset Disposal Income	427,400	1.5M	773,100	1.7M	1.1M
Asset Impairment Loss	978.0M	701.0M	3.0B	139.0M	-2.3M
Other Income	77.3M	114.0M	97.0M	208.0M	180.0M
Income Before Tax	-365.0M	395.0M	-1.3B	1.6B	2.4B
Income Tax	337.0M	243.0M	332.0M	478.0M	518.0M
+Net Income	-702.0M	152.0M	-1.6B	1.1B	1.8B
Net Margin %	-6.4%	1.1%	-10.6%	7.0%	11.5%
Net Income Attributable	-554.0M	319.0M	-1.5B	1.2B	1.9B
Minority Interest	-149.0M	-167.0M	-61.2M	-53.8M	-17.8M
Eps Basic	-0.51	0.29	-1.38	1.05	1.68
Eps Diluted	-0.51	0.29	-1.38	1.05	1.68

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	819.0M	694.0M	2.1B	1.2B	1.5B
Trading Financial Assets	404.0M	354.0M	726.0M	498.0M	386.0M
Accounts Receivable	893.0M	1.6B	1.6B	1.5B	1.3B
Notes Receivable	--	--	--	--	--
Notes And Accounts Receivable	893.0M	1.6B	1.6B	1.5B	1.3B
Prepayments	103.0M	138.0M	157.0M	87.9M	140.0M
Inventory	4.6B	4.9B	3.8B	3.8B	2.8B
Total Current Assets	7.5B	8.3B	9.0B	8.4B	8.0B
Long Term Equity Investment	1.1B	1.1B	1.1B	1.2B	1.3B
Fixed Assets	--	4.7B	5.0B	3.1B	2.4B
Fixed Assets Total	4.5B	4.7B	5.0B	3.1B	2.4B
Construction In Progress	--	1.2B	1.2B	2.8B	2.9B
Construction In Progress Total	1.1B	1.2B	1.2B	2.8B	2.9B
Intangible Assets	810.0M	949.0M	1.1B	1.2B	1.2B
Long Term Deferred Expenses	23.5M	9.3M	11.8M	13.5M	5.1M
Total Non Current Assets	11.8B	12.6B	13.0B	15.5B	14.9B
Total Assets	19.3B	20.9B	22.0B	23.9B	22.9B
Short Term Borrowings	486.0M	240.0M	639.0M	1.3B	2.6B
Accounts Payable	2.8B	2.4B	2.3B	2.4B	1.9B
Advance Receipts	--	--	--	--	--
Contract Liabilities	216.0M	238.0M	377.0M	242.0M	336.0M
Total Current Liabilities	7.1B	6.9B	7.0B	7.2B	7.8B
Long Term Borrowings	2.0B	2.1B	2.1B	1.9B	824.0M
Total Non Current Liabilities	2.4B	2.7B	2.7B	2.4B	1.3B
Total Liabilities	9.5B	9.5B	9.7B	9.5B	9.1B
Paid In Capital	1.1B	1.1B	1.1B	1.1B	1.1B
Capital Reserve	2.5B	2.5B	2.5B	3.4B	3.4B
Surplus Reserve	571.0M	571.0M	571.0M	571.0M	571.0M
Retained Earnings	6.7B	7.4B	8.2B	10.1B	9.6B
Minority Equity	-408.0M	-241.0M	-87.6M	25.2M	96.2M
Equity Attributable	10.2B	11.6B	12.4B	14.3B	13.7B
Total Equity	9.8B	11.4B	12.3B	14.3B	13.8B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	11.7B	13.3B	15.5B	16.2B	16.5B
Tax Refunds Received	3.5M	16.9M	202.0M	484,800	246,800
Total Operating Cash Inflow	11.8B	13.4B	15.8B	16.5B	16.7B
Cash Paid For Goods	2.9B	4.1B	2.7B	3.4B	3.3B
Cash Paid To Employees	1.0B	1.1B	989.0M	925.0M	801.0M
Taxes Paid	1.4B	1.8B	2.1B	2.3B	2.1B
Total Operating Cash Outflow	10.8B	13.6B	13.0B	15.2B	14.7B
Operating Cash Flow	940.0M	-196.0M	2.8B	1.3B	2.0B
Total Investing Cash Inflow	11.0M	434.0M	31.3M	101.0M	143.0M
Total Investing Cash Outflow	261.0M	602.0M	1.0B	757.0M	565.0M
Investing Cash Flow	-250.0M	-168.0M	-1.0B	-656.0M	-422.0M
Cash From Borrowings	2.3B	1.5B	2.1B	3.2B	3.1B
Dividends And Interest Paid	287.0M	1.2B	561.0M	776.0M	2.5B
Debt Repayments	1.8B	1.3B	2.7B	3.1B	2.4B
Total Financing Cash Inflow	2.3B	1.5B	2.3B	3.2B	3.1B
Total Financing Cash Outflow	2.9B	2.6B	3.3B	4.0B	5.0B
Financing Cash Flow	-565.0M	-1.1B	-988.0M	-771.0M	-1.9B
Net Change In Cash	125.0M	-1.4B	758.0M	-106.0M	-349.0M
Ending Cash Balance	818.0M	692.0M	2.1B	1.4B	1.5B
Capex	197.0M	530.0M	543.0M	434.0M	536.0M